Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 3/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.33 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24577112 | 0.90 | HDAC6 (0.34) | HDAC6CLK2LRRK2IKBKETBK1 | |
| SCHEMBL24577970 | 0.80 | WNT1 (0.34) | — | |
| SCHEMBL24576978 | 0.80 | GSK3B (0.41) | — | |
| SCHEMBL24577632 | 0.80 | GSK3B (0.41) | — | |
| SCHEMBL24578853 | 0.80 | KIT (0.34) | CLK2USP30 | |
| SCHEMBL24577551 | 0.79 | GSK3B (0.44) | CLK2LRRK2USP30 | |
| SCHEMBL24577174 | 0.78 | IKBKE (0.38) | IKBKETBK1BRD4 | |
| SCHEMBL24578874 | 0.77 | IKBKE (0.40) | HDAC6IKBKETBK1USP30 | |
| SCHEMBL24577155 | 0.77 | IKBKE (0.34) | HDAC6IKBKETBK1IRAK4 | |
| SCHEMBL24576968 | 0.74 | BRD4 (0.41) | HDAC6IKBKETBK1USP30BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |